USPTO serial 88049205
ACTIMED THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 24, 2022
- Examiner
- CORWIN, KEVIN SCOTT
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ACTIMED THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
M. Scott Alprin
M. Scott Alprin Alprin Law Offices, P.C.5 Pinehurst Circle, N.W.Washington, DC 20015UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, medical and therapeutic substances and preparations; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of cancers, and of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of physical function; pharmaceutical, medical and therapeutic substances and preparations for treatment and prevention of muscle wasting; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of patient tolerance of therapies, in particular anticancer therapy; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of cachexia, in particular cancer cachexia; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of the side effects of medical treatments, in particular of cancer treatments; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the lung; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the kidney; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the heart; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the liver; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the brain; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic heart failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic renal failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic liver failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic obstructive pulmonary disease; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of neurological-muscular disorders | ACTIVE | — |
| 044 | Information, advisory and consultancy services relating to medicine and healthcare; medical and surgical diagnosis and treatment services; medical analysis and reporting services relating to the treatment of patients; assessment and monitoring of patients; preparation of data and reports relating to medicine and healthcare; medical testing services relating to the diagnosis and treatment of illnesses, diseases and medical conditions; providing information relating to the management, preparation and dispensing of medications; medical, health, dentistry, veterinary and pharmaceutical services; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of cancers, and of severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to physical function and muscle wasting; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to patient tolerance of therapies, in particular anticancer therapy; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of cachexia, in particular cancer cachexia; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of the side effects of medical treatments, in particular of cancer treatments; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the lung; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the kidney; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the heart; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the liver; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the brain; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic heart failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic renal failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic liver failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic obstructive pulmonary disease; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of neurological-muscular disorders; advisory, information and consultancy services relating to all the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Actimed Therapeutics Limited
- Other trademarks owned by Actimed Therapeutics Limited
- Other trademarks owned by Actimed Therapeutics Limited
- Other trademarks in Class 005
- Other trademarks in Class 044
- Similar marks named ACTIMED THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 24, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 24, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 8, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 8, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 16, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 27, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 27, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 27, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 27, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 27, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 16, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 16, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 9, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Oct 1, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Oct 1, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Oct 1, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Sep 24, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 2, 2021 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Aug 6, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 6, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 6, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 17, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 17, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 12, 2020 | ALIE | ASSIGNED TO LIE | — |
| Jun 30, 2020 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jan 27, 2020 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jan 27, 2020 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jan 27, 2020 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jul 2, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 2, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 2, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 29, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 28, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 28, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 27, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 19, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 19, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 8, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 27, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 26, 2018 | NWAP | NEW APPLICATION ENTERED | — |